Similar Articles |
|
The Motley Fool December 13, 2007 Brian Lawler |
Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers. |
The Motley Fool October 16, 2007 Brian Lawler |
Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note. |
The Motley Fool November 6, 2007 Brian Lawler |
It's All About VELCADE at Millennium Millennium Pharmaceuticals announces a strong quarter of financial results. |
The Motley Fool August 5, 2008 Brian Lawler |
An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone. |
The Motley Fool May 2, 2007 Brian Lawler |
Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note. |
The Motley Fool February 7, 2008 Brian Lawler |
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition. |
The Motley Fool July 26, 2006 Brian Lawler |
Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note. |
The Motley Fool December 4, 2007 Brian Lawler |
Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash. |
The Motley Fool July 23, 2008 Brian Lawler |
No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results. |
The Motley Fool March 8, 2005 Charly Travers |
After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market. |
The Motley Fool August 29, 2008 Brian Lawler |
Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity? |
The Motley Fool June 11, 2008 Brian Lawler |
He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head. |
The Motley Fool January 29, 2008 Brian Lawler |
Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec. |
The Motley Fool February 6, 2009 Brian Orelli |
Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board. |
The Motley Fool May 29, 2008 Brian Lawler |
Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors. |
The Motley Fool April 25, 2008 Brian Lawler |
Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook. |
The Motley Fool December 4, 2009 Brian Orelli |
Our Final Offer (Maybe)! That's a FACT! Biogen ups its bid for Facet. |
The Motley Fool October 15, 2007 Brian Lawler |
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. |
The Motley Fool July 24, 2007 Brian Lawler |
Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line. |
The Motley Fool February 8, 2005 Charly Travers |
Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance. |
The Motley Fool January 9, 2008 Brian Lawler |
Checking In on Biogen Biogen Idec presents at the JPMorgan Healthcare Conference, reiterating its long-term guidance of 15% compound annual sales growth and 20% average non-GAAP earnings-per-share growth from 2007 through 2010. |
The Motley Fool July 21, 2010 Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool August 1, 2008 Brian Lawler |
Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug. |
The Motley Fool May 13, 2009 Brian Orelli |
Icahn's an Energizer Pit Bull He keeps going and doesn't let go. |
Chemistry World February 8, 2013 Andrew Turley |
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. |
The Motley Fool September 11, 2008 Brian Lawler |
ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet. |
The Motley Fool May 5, 2006 Stephen D. Simpson |
Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note. |
The Motley Fool October 31, 2011 Brian Orelli |
When You've Got It, You've Got It Biogen keeps its good-news streak going. |
The Motley Fool September 24, 2008 Brian Lawler |
Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems. |
The Motley Fool November 30, 2007 Brian Lawler |
MGI's Turn for "Strategic Alternatives" MGI Pharma is the latest in a growing list of drugmakers looking for someone to acquire them. The company may be a relatively more attractive takeover target than other drugmakers, because it's two lead drugs are unpartnered in the U.S. |
The Motley Fool June 1, 2009 Brian Orelli |
Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what? |
The Motley Fool September 4, 2009 Brian Orelli |
Takeover Likely? Management Says No! A hostile bid that management didn't want. Biogen Idec announced today that it's willing to buy Facet Biotech for $14.50 per share. |
The Motley Fool January 29, 2010 Brian Orelli |
Icahn Back to Batter Biogen The old guy has tenacity. |
The Motley Fool May 31, 2007 Tim Beyers |
Biogen's $3 Billion Bet There are times when a buyback is not only appropriate, but also smart. This is one of those times for Biogen Idec. It's a chance for management to deliver huge returns to long-suffering shareholders. |
The Motley Fool November 1, 2006 Brian Lawler |
Biogen Idec's Booming Results Even with guidance for 2006 non-GAAP earnings per share raised to more than $2.20, Biogen shares are trading at a reasonable 24 times earnings, considering the level of scale and sales growth it has exhibited this year. |
The Motley Fool February 10, 2010 Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool September 22, 2008 Brian Lawler |
Why Bristol-Myers Won't Pull Its ImClone Bid Bristol-Myers might drop its cash bid of $60 per share to acquire longtime partner ImClone Systems. |
The Motley Fool January 5, 2010 Brian Orelli |
Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out. |
The Motley Fool June 30, 2010 Ryan McBride |
Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately. |
The Motley Fool August 29, 2006 Brian Lawler |
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. |
The Motley Fool October 7, 2008 Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool November 18, 2008 Brian Orelli |
Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere. |
Chemistry World July 31, 2013 Daniel Johnson |
Perrigo bags Elan and its bargain Irish tax rates US drugmaker Perrigo has agreed to buy Irish pharma company Elan in a deal worth $8.6 billion. This hands Perrigo a base in low-tax Ireland and annual savings of up to $150 million in tax and operating costs. |
The Motley Fool June 8, 2010 Ryan McBride |
Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks. |
The Motley Fool December 16, 2009 Brian Orelli |
No Holiday Goodwill Twixt Biogen and Facet Biogen and Facet are still at it, as their nasty takeover fight continues. |
The Motley Fool March 16, 2007 Brian Lawler |
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. |
The Motley Fool August 1, 2008 Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? |
The Motley Fool July 17, 2009 Brian Orelli |
Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva. |
The Motley Fool March 11, 2005 Karl Thiel |
Better Times at Biogen IDEC Is now the time to buy this pharmaceutical? |
The Motley Fool August 21, 2008 Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |